Physician profile
Michelle E Allen
NPI 1902907561
$1,338.57
in general payments reported to CMS, 2019-2025
21 companies · $337 in 2025
The $337 reported for 2025 was more than what 77% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.00 · 2023: $496 · 2024: $487 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.28 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $330.23 | 2023-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $235.33 | 2023-2025 | Veozah |
| Abbvie INC. | $126.53 | 2024-2025 | |
| Glaxosmithkline, LLC. | $96.87 | 2023-2025 | Arexvy, Shingrix, Penmenvy |
| Sumitomo Pharma America, INC. | $91.53 | 2023-2025 | Gemtesa, Myfembree |
| Novo Nordisk INC | $73.24 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Mayne Pharma Commercial LLC | $64.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $64.39 | 2023-2024 | |
| Boston Scientific Corporation | $38.60 | 2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $33.53 | 2024 | Xarelto |
| Vertex Pharmaceuticals Incorporated | $19.74 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.73 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $18.51 | 2023 | Rexulti |
| Lilly USA, LLC | $18.07 | 2023 | Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $18.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.89 | 2024 | Rexulti |
| Dexcom, INC. | $17.24 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.76 | 2025 | M-M-R II, Gardasil 9, Proquad |
| Exeltis, USA INC. | $14.90 | 2023 | Slynd |
| Phathom Pharmaceuticals, INC. | $3.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.